H. Lecaer

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Teresa Morán, Jia Wei, Manuel Cobo et al. · Annals of Oncology · 2014 · 30 citations · Full text

Medicine, Cancer Biology, Oncology +17

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

H. Lecaer, Fabrice Barlési, R. Corre et al. · British Journal of Cancer · 2011 · 26 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study)

H. Lecaer, Laurent Greillier, R. Corre et al. · Lung Cancer · 2012 · 24 citations

Medicine, Geriatric Medicine, Oncology +17

An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study

H. Lecaer, P. Fournel, H. Jullian et al. · Critical Reviews in Oncology/Hematology · 2007 · 21 citations

Medicine, Geriatric Medicine, Oncology +13

An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study

H. Lecaer, Fabrice Barlési, G. Robinet et al. · Lung Cancer · 2007 · 18 citations

Medicine, Oncology, Pharmacotherapy +15